No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SMAR240517P60000
- 13.90
- 0.000.00%
15min DelayTrading Jan 18 10:42 ET
0.00High0.00Low
0.00Open13.90Pre Close0 Volume0 Open Interest60.00Strike Price0.00Turnover352.08%IV-0.52%PremiumMay 17, 2024Expiry Date18.29Intrinsic Value100Multiplier1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.9356Delta0.0136Gamma2.25Leverage Ratio-0.2287Theta-0.0019Rho-2.11Eff Leverage0.0033Vega
Intraday
- 5D
- 1D
News
Form 144 | Smartsheet(SMAR.US) Officer Proposes to Sell 218.07K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $Smartsheet(SMAR.US)$ Officer Godbole Pete intends to sell 5,202 shares of its common stock on May 15, with a total market value of approximately $218.07K. Godbole Pe
Monday.com Surges as Company Boosts Full-year Guidance
Smartsheet (NYSE:SMAR) Shareholders Have Endured a 26% Loss From Investing in the Stock Three Years Ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the risk of stock picking is that you will likely buy under-perfor
3 Mid-Cap Stocks That Will Help You Build Long-Term Wealth
Mid-cap stocks, from companies with a market capitalization between $2 billion and $10 billion, according to FINRA, are easy to overlook.
Smartsheet to Announce First Quarter of Fiscal Year 2025 Financial Results on June 5, 2024
Smartsheet Inc. (NYSE:SMAR), the enterprise work management platform, today announced that it will release its financial results for its first quarter of fiscal year 2025, which ended April 30, 2024, after the close of
Express News | NYSE Order Imbalance 54228.0 Shares on Buy Side
Comments
Morning Movers
Gapping up
$Madrigal Pharmaceuticals(MDGL.US$ stock jumped 25% after the U.S. Food and Drug Administration approved its drug for a fatty liver disease known as non-alcoholic steatohepatitis.
$Rivian Automotive(RIVN.US$ stock rose 3.9% after Piper Sandler upgraded its stance on the EV manufacturer to overweight, citing growing excitement surrounding new product launches.
Gapping down
$Adobe(ADBE.US$ stock f...
Gapping up
$Madrigal Pharmaceuticals(MDGL.US$ stock jumped 25% after the U.S. Food and Drug Administration approved its drug for a fatty liver disease known as non-alcoholic steatohepatitis.
$Rivian Automotive(RIVN.US$ stock rose 3.9% after Piper Sandler upgraded its stance on the EV manufacturer to overweight, citing growing excitement surrounding new product launches.
Gapping down
$Adobe(ADBE.US$ stock f...
27
No recent insider transactions at Smartsheet isn't concerning, but the lack of insider buying over the past year is uninspiring. Investors should note 2 warning signs regarding Smartsheet.
Despite impressive revenue growth, Smartsheet's share price drop suggests growth may have fallen short of expectations. However, this could be a buying opportunity. The company's future earnings are crucial for shareholders. The total return was 2.2%, below market average.
1
Smartsheet Inc.'s high P/S ratio is likely due to investor expectations of continued strong revenue performance. Shareholders' confidence in future revenues is keeping the P/S high.
The fact that insiders sold Smartsheet shares recently and didn't buy any, coupled with the long term picture, doesn't offer much comfort about the company's outlook despite their substantial ownership.
Read more